SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

$RARI is an ERC-20 token that controls the RARI Foundation treasury and governs the Rarible protocol and RARI Chain. The token was issued in 2020 with a max. supply of 25 million $RARI.

Rarible

Rarible is trending as investors highlight its ultra-low circulating supply and small market cap as key catalysts for significant potential upside. The community is actively discussing the possibility of a major price breakout, with many drawing comparisons to previous market cycles and pinning hopes on upcoming exchange listings or an broader resurgence in the NFT sector.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is currently a focal point for the community due to renewed institutional interest and a wave of activity surrounding its potential in real-world asset (RWA) tokenization and post-quantum security research. Investors are actively debating the long-term viability of the project, weighing concerns over its historical price performance against optimism that new governance developments and potential regulatory clarity will drive future utility.

BENQI is a decentralized non-custodial liquidity market protocol, built on Avalanche. The protocol enables users to effortlessly lend, borrow, and earn interest with their digital assets. Depositors providing liquidity to the protocol may earn passive income, while borrowers are able to borrow in an over-collateralized manner.

Benqi Finance

Benqi Finance is seeing significant community discussion driven by its status as a major DeFi project on the Avalanche network, with investors closely watching its total value locked and potential for real-world asset integration. While some holders express frustration over recent price volatility and accumulation struggles, many participants remain optimistic about its long-term utility and ecosystem growth alongside AVAX.

Monad is a high-performance Layer 1 blockchain that processes 10,000 transactions per second with near-zero fees. The platform delivers high performance without compromising on security or decentralization, creating the infrastructure needed for complex applications that require high-frequency activity.  One of Monad’s key innovations lies in how it handles transaction processing. Instead of processing transactions one at a time like traditional blockchains, Monad processes multiple transactions simultaneously through parallel execution.   The system separates the agreement process from the execution process, allowing validators to first agree on which transactions to include and in what order, then having more time to execute those transactions without slowing down consensus. This approach, combined with a custom-built database called MonadDB, dramatically increases throughput while maintaining accuracy.  Monad also offers complete EVM compatibility, where applications built for Ethereum work on Monad without any code modifications, and users can connect with familiar wallets like MetaMask just as they would on Ethereum. Developers can immediately tap into Ethereum's established ecosystem of tools, libraries, and applications while benefitting from Monad’s performance improvements. The platform also runs on consumer-grade hardware rather than expensive specialized equipment, making it accessible for more people to participate in securing the network.  Monad has raised approximately 244 million dollars in total funding across multiple rounds. The company secured 19 million dollars in a seed round in February 2023 led by Dragonfly Capital, followed by a 225 million dollar Series A round in April 2024 led by Paradigm at a 3 billion dollar valuation. Other notable investors include Electric Capital, Greenoaks, Coinbase Ventures, and prominent angel investors such as Naval Ravikant.

Monad

Monad is seeing heightened trader attention as the community debates its potential as a high-performance Layer 1 alternative to established networks like Ethereum and Solana. Discussions are currently dominated by a mix of long-term optimism regarding its ecosystem growth and staking utility versus concerns over recent price volatility and token distribution schedules.

Maul Coin

Maul Coin is currently trending as its community actively rallies to drive visibility and growth, focusing on aggressive social media promotion and a "Maul" mentality to gain traction without a traditional marketing budget. The discourse is heavily centered on the active presence of the developer, building a grassroots movement, and the collective push to reach significant milestones like a dollar-based valuation and increased watcher counts on trading platforms.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is experiencing a surge in community interest driven by anticipation of upcoming cannabis-related catalysts and the approach of annual industry milestones. Supporters are actively highlighting the project's organic growth and long-term vision, positioning it as a culture-driven alternative to traditional cannabis stocks.

Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. Its products include Biorphen, Alaway Preservative Free, zonisamide oral suspension, topiramate oral suspension, lamotrigine for oral suspension, cysteine injection, and ephedrine ready-to-use injection. The company was founded in April 2017 and is headquartered in Deer Park, IL.

Eton Pharmaceuticals Inc

Eton Pharmaceuticals is currently trending due to its recent FDA approval for DESMODA, a milestone that community members view as a significant step in the company's evolution from a biotech hopeful to a revenue-generating commercial player. The community is actively discussing the stock's potential as an undervalued "hidden gem," citing strong recent financial performance, successful portfolio expansion, and an upcoming earnings report as key drivers for potential long-term growth.

Taseko Mines Ltd. operates as a mining company which engages in the acquisition, development, and operation of mineral deposits. It holds interest in the Gibraltar, Florence Copper, Aley Niobium, Yellowhead, New Prosperity, and Harmony projects. The company was founded on April 15, 1966 and is headquartered in Vancouver, Canada.

Taseko Mines Ltd.

Taseko Mines is drawing significant investor interest as it nears the commercial launch of its Florence Copper project in Arizona, which is expected to double production capacity and establish the company as a key domestic copper source. The community remains focused on the project's ability to drive long-term cash flow, while broader discourse highlights the stock's leverage to rising global copper demand from AI, electrification, and supply constraints.

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.

Cingulate Inc

Cingulate Inc. is trending as investors rally around the company's upcoming May 31 PDUFA date for its ADHD candidate, CTx-1301, while closely monitoring expectations for imminent U.S. patent approval. The community is actively discussing the stock's potential for significant upside based on its low float and the massive market opportunity for its precision-timed drug delivery platform.

ConocoPhillips is an exploration and production company, which engages in the exploration, production, transport, and marketing of crude oil, bitumen, and natural gas. It operates through the following geographical segments: Alaska, Lower 48, Canada, Europe, Middle East, and North Africa, Asia Pacific, and Other International. The Alaska segment explores for, produces, transports and markets crude oil, natural gas and NGLs. The Lower 48 segment consists of operations located in the 48 contiguous U.S. states and the Gulf of Mexico. The Canada segment refers to oil sands development in the Athabasca Region of northeastern Alberta and a liquids-rich unconventional play in western Canada. The Europe, Middle East, and North Africa segment includes operations in the Norwegian sector of the North Sea, the Norwegian Sea, Qatar, Libya, Equatorial Guinea and commercial and terminalling operations in the U.K. The Asia Pacific segment focuses on explorations and product operations in China, Indonesia, Malaysia, and Australia. The Other International segment handles exploration activities in Columbia and Argentina. The company was founded by Isaac Elder Blake on November 25, 1875 and is headquartered in Houston, TX.

Conoco Phillips

ConocoPhillips is currently attracting significant attention as investors react to a planned 20-25% reduction in its global workforce, a move widely interpreted as a cost-cutting measure to prepare for a lower oil price environment. The community is actively debating the stock's future amid this restructuring, with many investors weighing the company's long-term operational resilience against broader sector headwinds and ongoing volatility in commodity markets.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

C4 Therapeutics, Inc. (NASDAQ:CCCC) Short Interest Update

C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) was the target of a large increase in short interest during the month of March. As of March 13th, there was short interest totaling 13,534,910...

Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year?

Here is how C4 Therapeutics, Inc. (CCCC) and Align Technology (ALGN) have performed compared to their sector so far this year.

C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) have been given an average rating of "Moderate Buy" by the seven ratings firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating and five have i...

C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) was the recipient of a large increase in short interest during the month of February. As of February 27th, there was short interest totaling...

C4 Therapeutics Details MOMENTUM Phase 2 Start, Eyes Near-Term Decision on EGFR Program at Barclays Confab

C4 Therapeutics (NASDAQ:CCCC) outlined near-term clinical plans for its targeted protein degradation pipeline during a presentation at Barclays' 28th Annual Global Healthcare Conference, highlighting...

C4 Therapeutics Maps Accelerated Approval Path for Myeloma Drug Cemsidomide at TD Cowen Conference

C4 Therapeutics (NASDAQ:CCCC) used a presentation at TD Cowen's 46th Annual Healthcare Conference to outline its near- and mid-term clinical plans, emphasizing its lead multiple myeloma program...

Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice

Does C4 Therapeutics, Inc. (CCCC) have what it takes to be a top stock pick for momentum investors? Let's find out.

Is BrightSpring Health Services, Inc. (BTSG) Stock Outpacing Its Medical Peers This Year?

Here is how BrightSpring Health Services, Inc. (BTSG) and C4 Therapeutics, Inc. (CCCC) have performed compared to their sector so far this year.

Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types

Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types PR Newswire VANCOUVER...

C4 Therapeutics (NASDAQ:CCCC) Upgraded to Hold at Wall Street Zen

Wall Street Zen raised shares of C4 Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Saturday...

C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. It develops the Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Watertown, MA.

C4 Therapeutics Inc

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.27	--	--	N/A
Q4 '25	-$0.30	-$0.18	39.02%	BEAT
Q3 '25	-$0.41	-$0.44	-8.45%	MISSED
Q2 '25	-$0.38	-$0.37	3.65%	BEAT
Q1 '25	-$0.44	-$0.37	16.29%	BEAT

CCCC
C4 Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest CCCC News

CCCCC4 Therapeutics Inc